根据美国证券交易委员会（SEC）提交的文件，Apogee Therapeutics公司已同意，依据其与Paragon达成的IL-31R（白细胞介素-31受体）许可协议，向后者支付最高可达2325万美元的里程碑款项。
该协议明确了在药物研发与商业化进程中达成特定目标时，Apogee需履行的财务义务。此次披露的金额上限涵盖了协议中设定的各项里程碑事件，凸显了Apogee为推进其IL-31R相关项目所承诺的潜在投资规模。
这一安排通常见于生物技术领域的许可合作中，旨在激励被许可方（此例中为Paragon）成功推进授权资产，同时许可方（Apogee）则通过分期付款的方式管理其财务支出。文件显示，款项的支付将与未来研发进展及监管审批等关键节点紧密挂钩。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.